New strategic insights into managing fungal biofilms

Elisa Borghi, Giulia Morace, Francesca Borgo, Ranjith Rajendran, Leighann Sherry, Chris Nile, Gordon Ramage

Research output: Contribution to journalArticle

Abstract

Fungal infections have dramatically increased in the last decades in parallel with an increase of populations with impaired immunity, resulting from medical conditions such as cancer, transplantation, or other chronic diseases. Such opportunistic infections result from a complex relationship between fungi and host, and can range from self-limiting to chronic or life-threatening infections. Modern medicine, characterized by a wide use of biomedical devices, offers new niches for fungi to colonize and form biofilm communities. The capability of fungi to form biofilms is well documented and associated with increased drug tolerance and resistance. In addition, biofilm formation facilitates persistence in the host promoting a persistent inflammatory condition. With a limited availability of antifungals within our arsenal, new therapeutic approaches able to address both host and pathogenic factors that promote fungal disease progression, i.e., chronic inflammation and biofilm formation, could represent an advantage in the clinical setting. In this paper we discuss the antifungal properties of myriocin, fulvic acid, and acetylcholine in light of their already known anti-inflammatory activity and as candidate dual action therapeutics to treat opportunistic fungal infections.
Original languageEnglish
Article number1077
Number of pages6
JournalFrontiers in Microbiology
Volume6
DOIs
Publication statusPublished - 6 Oct 2015
Externally publishedYes

Fingerprint

Biofilms
Mycoses
Fungi
Opportunistic Infections
Drug Tolerance
Modern 1601-history
Host Specificity
Drug Resistance
Acetylcholine
Disease Progression
Immunity
Chronic Disease
Anti-Inflammatory Agents
Transplantation
Inflammation
Equipment and Supplies
Therapeutics
Infection
Population
Neoplasms

Keywords

  • Biofilm-related infections
  • antifungal resistance
  • fulvic acid
  • acetylcholine
  • myriocin

Cite this

Borghi, E., Morace, G., Borgo, F., Rajendran, R., Sherry, L., Nile, C., & Ramage, G. (2015). New strategic insights into managing fungal biofilms. Frontiers in Microbiology, 6, [1077]. https://doi.org/10.3389/fmicb.2015.01077
Borghi, Elisa ; Morace, Giulia ; Borgo, Francesca ; Rajendran, Ranjith ; Sherry, Leighann ; Nile, Chris ; Ramage, Gordon. / New strategic insights into managing fungal biofilms. In: Frontiers in Microbiology. 2015 ; Vol. 6.
@article{6df13faeb2bc48efb47f7f73af21f8a7,
title = "New strategic insights into managing fungal biofilms",
abstract = "Fungal infections have dramatically increased in the last decades in parallel with an increase of populations with impaired immunity, resulting from medical conditions such as cancer, transplantation, or other chronic diseases. Such opportunistic infections result from a complex relationship between fungi and host, and can range from self-limiting to chronic or life-threatening infections. Modern medicine, characterized by a wide use of biomedical devices, offers new niches for fungi to colonize and form biofilm communities. The capability of fungi to form biofilms is well documented and associated with increased drug tolerance and resistance. In addition, biofilm formation facilitates persistence in the host promoting a persistent inflammatory condition. With a limited availability of antifungals within our arsenal, new therapeutic approaches able to address both host and pathogenic factors that promote fungal disease progression, i.e., chronic inflammation and biofilm formation, could represent an advantage in the clinical setting. In this paper we discuss the antifungal properties of myriocin, fulvic acid, and acetylcholine in light of their already known anti-inflammatory activity and as candidate dual action therapeutics to treat opportunistic fungal infections.",
keywords = "Biofilm-related infections, antifungal resistance, fulvic acid, acetylcholine, myriocin",
author = "Elisa Borghi and Giulia Morace and Francesca Borgo and Ranjith Rajendran and Leighann Sherry and Chris Nile and Gordon Ramage",
year = "2015",
month = "10",
day = "6",
doi = "10.3389/fmicb.2015.01077",
language = "English",
volume = "6",
journal = "Frontiers in Microbiology",
issn = "1664-302X",
publisher = "Frontiers Media",

}

Borghi, E, Morace, G, Borgo, F, Rajendran, R, Sherry, L, Nile, C & Ramage, G 2015, 'New strategic insights into managing fungal biofilms' Frontiers in Microbiology, vol. 6, 1077. https://doi.org/10.3389/fmicb.2015.01077

New strategic insights into managing fungal biofilms. / Borghi, Elisa; Morace, Giulia ; Borgo, Francesca ; Rajendran, Ranjith; Sherry, Leighann; Nile, Chris ; Ramage, Gordon.

In: Frontiers in Microbiology, Vol. 6, 1077, 06.10.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - New strategic insights into managing fungal biofilms

AU - Borghi, Elisa

AU - Morace, Giulia

AU - Borgo, Francesca

AU - Rajendran, Ranjith

AU - Sherry, Leighann

AU - Nile, Chris

AU - Ramage, Gordon

PY - 2015/10/6

Y1 - 2015/10/6

N2 - Fungal infections have dramatically increased in the last decades in parallel with an increase of populations with impaired immunity, resulting from medical conditions such as cancer, transplantation, or other chronic diseases. Such opportunistic infections result from a complex relationship between fungi and host, and can range from self-limiting to chronic or life-threatening infections. Modern medicine, characterized by a wide use of biomedical devices, offers new niches for fungi to colonize and form biofilm communities. The capability of fungi to form biofilms is well documented and associated with increased drug tolerance and resistance. In addition, biofilm formation facilitates persistence in the host promoting a persistent inflammatory condition. With a limited availability of antifungals within our arsenal, new therapeutic approaches able to address both host and pathogenic factors that promote fungal disease progression, i.e., chronic inflammation and biofilm formation, could represent an advantage in the clinical setting. In this paper we discuss the antifungal properties of myriocin, fulvic acid, and acetylcholine in light of their already known anti-inflammatory activity and as candidate dual action therapeutics to treat opportunistic fungal infections.

AB - Fungal infections have dramatically increased in the last decades in parallel with an increase of populations with impaired immunity, resulting from medical conditions such as cancer, transplantation, or other chronic diseases. Such opportunistic infections result from a complex relationship between fungi and host, and can range from self-limiting to chronic or life-threatening infections. Modern medicine, characterized by a wide use of biomedical devices, offers new niches for fungi to colonize and form biofilm communities. The capability of fungi to form biofilms is well documented and associated with increased drug tolerance and resistance. In addition, biofilm formation facilitates persistence in the host promoting a persistent inflammatory condition. With a limited availability of antifungals within our arsenal, new therapeutic approaches able to address both host and pathogenic factors that promote fungal disease progression, i.e., chronic inflammation and biofilm formation, could represent an advantage in the clinical setting. In this paper we discuss the antifungal properties of myriocin, fulvic acid, and acetylcholine in light of their already known anti-inflammatory activity and as candidate dual action therapeutics to treat opportunistic fungal infections.

KW - Biofilm-related infections

KW - antifungal resistance

KW - fulvic acid

KW - acetylcholine

KW - myriocin

U2 - 10.3389/fmicb.2015.01077

DO - 10.3389/fmicb.2015.01077

M3 - Article

VL - 6

JO - Frontiers in Microbiology

JF - Frontiers in Microbiology

SN - 1664-302X

M1 - 1077

ER -

Borghi E, Morace G, Borgo F, Rajendran R, Sherry L, Nile C et al. New strategic insights into managing fungal biofilms. Frontiers in Microbiology. 2015 Oct 6;6. 1077. https://doi.org/10.3389/fmicb.2015.01077